ANI Pharmaceuticals Inc当前公司基本面数据相对健康,增长潜力很大。当前估值合理,在药品行业排名3/158位。机构持股占比非常高,近一月多位分析师给出公司评级为买入。最高目标价108.00。中期看,股价处于下降通道。近一个月,市场表现一般,但公司基本面和技术面得分较高。目前股价在压力位和支撑位之间,可以做区间波段操作。
ANI Pharmaceuticals Inc评分
相关信息
行业排名
3 / 158
全市场排名
20 / 4582
所属行业
药品
压力支撑
由于公司未披露,未能获取相关数据
多维评测
本期评分
上期评分
分析师目标
根据
9
位分析师
买入
评级
108.000
目标均价
+32.78%
涨幅空间
数据免责声明:分析师评级与目标价由LSEG提供,仅供参考,不应当作投资建议
ANI Pharmaceuticals Inc亮点
亮点风险
ANI Pharmaceuticals, Inc. is a diversified biopharmaceutical company engaged in developing, manufacturing, and commercializing therapeutics. Its Rare Disease and Brands segment consists of two reporting units. The Rare Disease unit consists of operations related to the development, manufacturing, and marketing of branded pharmaceutical products, with a focus on products used in the treatment of patients with rare disease conditions and consists of operations related to Cortrophin Gel, ILUVIEN and YUTIQ. In addition, the Brands reporting unit includes a portfolio of over 16 brand products that are principally sold in genericized markets. Its Generics and Other segment consist of operations related to the development, manufacturing, and marketing of generic pharmaceutical products, including those sold through traditional wholesale and retail sales channels, sales of contract manufactured products, royalties on contract manufactured products, product development services, and others.
ANI Pharmaceuticals, Inc. is a diversified biopharmaceutical company engaged in developing, manufacturing, and commercializing therapeutics. Its Rare Disease and Brands segment consists of two reporting units. The Rare Disease unit consists of operations related to the development, manufacturing, and marketing of branded pharmaceutical products, with a focus on products used in the treatment of patients with rare disease conditions and consists of operations related to Cortrophin Gel, ILUVIEN and YUTIQ. In addition, the Brands reporting unit includes a portfolio of over 16 brand products that are principally sold in genericized markets. Its Generics and Other segment consist of operations related to the development, manufacturing, and marketing of generic pharmaceutical products, including those sold through traditional wholesale and retail sales channels, sales of contract manufactured products, royalties on contract manufactured products, product development services, and others.